Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
04 2020
Historique:
received: 26 09 2019
accepted: 04 10 2019
pubmed: 23 12 2019
medline: 6 1 2021
entrez: 23 12 2019
Statut: ppublish

Résumé

This study aimed to investigate the accuracy of a broad range of echocardiographic variables to develop multiparametric scores to diagnose CA in patients with proven light chain (AL) amyloidosis or those with increased heart wall thickness who had amyloid was suspected. We also aimed to further characterize the structural and functional changes associated with amyloid infiltration. Cardiac amyloidosis (CA) is a serious but increasingly treatable cause of heart failure. Diagnosis is challenging and frequently unclear at echocardiography, which remains the most often used imaging tool. We studied 1,187 consecutive patients evaluated at 3 referral centers for CA and analyzed morphological, functional, and strain-derived echocardiogram parameters with the aim of developing a score-based diagnostic algorithm. Cardiac amyloid burden was quantified by using extracellular volume measurements at cardiac magnetic resonance. A total of 332 patients were diagnosed with AL amyloidosis and 339 patients with transthyretin CA. Concentric remodeling and strain-derived parameters displayed the best diagnostic performance. A multivariable logistic regression model incorporating relative wall thickness, E wave/e' wave ratio, longitudinal strain, and tricuspid annular plane systolic excursion had the greatest diagnostic performance in AL amyloidosis (area under the curve: 0.90; 95% confidence interval: 0.87 to 0.92), whereas the addition of septal apical-to-base ratio yielded the best diagnostic accuracy in the increased heart wall thickness group (area under the curve: 0.80; 95% confidence interval: 0.85 to 0.90). Specific functional and structural parameters characterize different burdens of CA deposition with different diagnostic performances and enable the definition of 2 scores that are sensitive and specific tools with which diagnose or exclude CA.

Sections du résumé

OBJECTIVES
This study aimed to investigate the accuracy of a broad range of echocardiographic variables to develop multiparametric scores to diagnose CA in patients with proven light chain (AL) amyloidosis or those with increased heart wall thickness who had amyloid was suspected. We also aimed to further characterize the structural and functional changes associated with amyloid infiltration.
BACKGROUND
Cardiac amyloidosis (CA) is a serious but increasingly treatable cause of heart failure. Diagnosis is challenging and frequently unclear at echocardiography, which remains the most often used imaging tool.
METHODS
We studied 1,187 consecutive patients evaluated at 3 referral centers for CA and analyzed morphological, functional, and strain-derived echocardiogram parameters with the aim of developing a score-based diagnostic algorithm. Cardiac amyloid burden was quantified by using extracellular volume measurements at cardiac magnetic resonance.
RESULTS
A total of 332 patients were diagnosed with AL amyloidosis and 339 patients with transthyretin CA. Concentric remodeling and strain-derived parameters displayed the best diagnostic performance. A multivariable logistic regression model incorporating relative wall thickness, E wave/e' wave ratio, longitudinal strain, and tricuspid annular plane systolic excursion had the greatest diagnostic performance in AL amyloidosis (area under the curve: 0.90; 95% confidence interval: 0.87 to 0.92), whereas the addition of septal apical-to-base ratio yielded the best diagnostic accuracy in the increased heart wall thickness group (area under the curve: 0.80; 95% confidence interval: 0.85 to 0.90).
CONCLUSIONS
Specific functional and structural parameters characterize different burdens of CA deposition with different diagnostic performances and enable the definition of 2 scores that are sensitive and specific tools with which diagnose or exclude CA.

Identifiants

pubmed: 31864973
pii: S1936-878X(19)31007-1
doi: 10.1016/j.jcmg.2019.10.011
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

909-920

Subventions

Organisme : British Heart Foundation
ID : FS/18/21/33447
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Michele Boldrini (M)

National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom; Emergency Department, Internal Medicine Department, Amyloidosis Research and Treatment Center, Istituto di Ricerca a Carattere Clinico e Scientifico Policlinico San Matteo Foundation, Pavia, Italy.

Francesco Cappelli (F)

Tuscan Regional Amyloid Centre, Careggi University Hospital, Florence, Italy.

Liza Chacko (L)

National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom.

Maria Alejandra Restrepo-Cordoba (MA)

Department of Cardiology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain.

Angela Lopez-Sainz (A)

Department of Cardiology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain.

Alberto Giannoni (A)

Fondazione Toscana Gabriele Monasterio, Pisa, Italy; Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.

Alberto Aimo (A)

National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom; Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.

Andrea Baggiano (A)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Ana Martinez-Naharro (A)

National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom.

Carol Whelan (C)

National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom.

Cristina Quarta (C)

National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom.

Claudio Passino (C)

Fondazione Toscana Gabriele Monasterio, Pisa, Italy; Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.

Vincenzo Castiglione (V)

Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.

Vladyslav Chubuchnyi (V)

Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Valentina Spini (V)

Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Claudia Taddei (C)

Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Giuseppe Vergaro (G)

Fondazione Toscana Gabriele Monasterio, Pisa, Italy; Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.

Aviva Petrie (A)

Eastman Dental Institute, University College London, Grays Inn Road, London, United Kingdom.

Luis Ruiz-Guerrero (L)

Department of Cardiology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain.

Vanessa Moñivas (V)

University Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain.

Susana Mingo-Santos (S)

University Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain.

Jesus G Mirelis (JG)

Department of Cardiology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain.

Fernando Dominguez (F)

Department of Cardiology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain.

Esther Gonzalez-Lopez (E)

Department of Cardiology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain.

Stefano Perlini (S)

Emergency Department, Internal Medicine Department, Amyloidosis Research and Treatment Center, Istituto di Ricerca a Carattere Clinico e Scientifico Policlinico San Matteo Foundation, Pavia, Italy.

Gianluca Pontone (G)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Julian Gillmore (J)

National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom.

Philip N Hawkins (PN)

National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom.

Pablo Garcia-Pavia (P)

Department of Cardiology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain; University Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain.

Michele Emdin (M)

Fondazione Toscana Gabriele Monasterio, Pisa, Italy; Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.

Marianna Fontana (M)

National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom. Electronic address: m.fontana@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH